The two receptor classes act at different points in the pathway. Nicotinic receptors receive acetylcholine from preganglionic neurons in autonomic ganglia, whereas muscarinic receptors mediate the response of target tissues to acetylcholine released by postganglionic neurons. This distinction allows pharmacologists to predict whether a drug will primarily influence ganglionic transmission or organ-specific functions such as cardiac, gastrointestinal, glandular, or bladder activity.
Receptor location links a pharmacological action to a physiological outcome. Modifying muscarinic signaling in the heart can change heart rate, while altering the same receptor-mediated pathway in the gastrointestinal tract, glands, airways, or bladder can affect different functions. Consequently, identifying the target tissue is essential for anticipating both the intended response and unwanted effects of drugs that modify parasympathetic activity.
Cholinergic agonists enhance signaling through pathways normally activated by acetylcholine, while antagonists reduce or block those effects. Their actions can therefore shift organ function in contrasting directions, depending on the tissue involved. Pharmacologists use this agonist-antagonist comparison to relate receptor activity to changes in heart rate, pupil diameter, airway tone, intestinal motility, and bladder function.
The affected organ depends largely on which parasympathetic receptor-mediated pathway the drug modifies and where that pathway is active. Because acetylcholine signaling participates in several target tissues, one pharmacological intervention may influence different organ functions or produce adverse effects beyond the intended site. Mapping receptor action to tissue response helps distinguish therapeutic effects from predictable autonomic consequences.
A practical analysis begins by identifying whether the drug acts as a cholinergic agonist or antagonist, then locating the relevant receptor stage and target tissue. Pharmacologists next relate that action to observable changes such as heart rate, pupil diameter, airway tone, intestinal motility, or bladder function. This framework supports prediction of therapeutic responses and adverse effects without treating every organ effect as independent.
Changes in heart rate, pupil diameter, airway tone, intestinal motility, and bladder function provide informative readouts of altered parasympathetic signaling. These outcomes span cardiovascular, ocular, respiratory, gastrointestinal, and urinary functions, making them useful for connecting receptor-level pharmacology with organ-level responses. In research and therapeutics, the pattern of changes helps indicate which autonomic functions a drug has modified.